Patients with oncogene-driven lung cancer have limited therapeutic options after
progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role …

For many years, researchers have been trying to develop the most effective ways to fight
lung cancer, which is the cause of the largest number of cancer-related deaths among men …

Both ceritinib (CER) and programmed cell death (PD)‐1/PD ligand‐1 (PD‐L1) have brought
significant breakthroughs for anaplastic lymphoma kinase (ALK)‐rearranged non‐small‐cell …

Interventions: The patient started first-line systemic treatment with pembrolizumab reporting
stable disease; at progression, she received second-line treatment with crizotinib. The …

Background The identification of NTRK fusions in tumours has become critically important
due to the actionable events predictive of response to TRK inhibitor. It is not clear whether …

Introduction The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune
checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK …

Background PD‐L1 expression in tumor cells has been associated with the efficacy of
immune checkpoint inhibitors in non‐small cell lung cancer (NSCLC). The aim of this study …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 3): S290-S293 tlcr. amegroups. com all the studies. Based on the results of these …

Our understanding of non-small cell lung cancer (NSCLC) has transformed with the recent
discovery of therapeutically targetable oncogenic drivers, including gene fusions or …

One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by
rearrangement of the anaplastic lymphoma kinase (ALK). The increasing knowledge over …